Since αCT1 has also shown promising results in vivo against arrhythmia and ischemia/reperfusion injury, clinical trials utilizing αCT1 or other agents to promote Cx43 S368 phosphorylation in cardiac diseases seem viable (178, 229). Here, TRAF3IP2 is linked to heart disorder.